QIAGEN to acquire stake in Alacris, gaining access to biomarker pipeline for use in personalized healthcare assays
13-Jan-2011 -
QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient’s genomic profile, and for the acquisition of an exclusive option to ...
biomarker
cancer